Medindia

X

Oral Therapy Drug for Multiple Sclerosis Gets Approval

by Julia Samuel on  February 17, 2015 at 11:00 AM Drug News   - G J E 4
The national drug controller, Drug Controller General of India (DCGI), has approved a new oral therapy drug for multiple sclerosis, developed by Biogen Idec Biotech India.

The company has received approval for the first oral therapy drug for multiple sclerosis, Tecfidera by the DCGI.
Oral Therapy Drug for Multiple Sclerosis Gets Approval
Oral Therapy Drug for Multiple Sclerosis Gets Approval
Advertisement

Biogen Idec India Acting Managing Director Pooja Vatsyayan said, "We believe Tecfidera provides a new option for patients in India, particularly as it provides the convenience of oral dosing."

Advertisement
The clinical trials conducted for the approval of the drug involved two-phase III studies more than 2600 patients all around the world. Patients from India also were part of clinical research, Biogen Idec India said.

Tecfidera is the first oral drug for the treatment of relapsing-remitting multiple sclerosis (RRMS) in India, it added.

Multiple sclerosis is a disease, which affects brain and spinal cord and is the most common cause of non-traumatic neurological disability afflicting young adults, Biogen Idec India said.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All